Cytosorbents (CTSO) Tops Q3 EPS by 1c, Misses on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 rises; Apple and Palantir set to report results
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts CTSO Hot Sheet
Join SI Premium – FREE
Cytosorbents (NASDAQ: CTSO) reported Q3 EPS of ($0.04), $0.01 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $9.5 million versus the consensus estimate of $10.4 million.
For earnings history and earnings-related data on Cytosorbents (CTSO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rosenblatt keeps Buy rating on Marvell after Lumentum acquisition
- Neogen Corp. (NEOG) spreader of 5K contracts of April 10 puts and April 15 calls
- Pinduoduo (PDD) call put ratio 6.5 calls to 1 put with a focus on January 95 calls as share price up 4.7%
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
